Virus-like particles as universal influenza vaccines.

Virus-like particles as universal influenza vaccines.
复制标题

DOI:
10.1586/erv.12.70
复制
发表时间:
2012-08
影响因子:
6.2
通讯作者:
Compans RW
Compans RW
中科院分区:
医学2区
文献类型:
--
作者:
Kang SM;Kim MC;Compans RW

文献摘要

参考文献

被引文献

相似文献

目前的流感疫苗主要是针对流感病毒株特异的血凝素抗原诱导免疫,在控制新的大流行病毒暴发方面效果不佳。开发通用疫苗的一种方法是将高度保守的抗原表位呈现在免疫原性构象中,如病毒样颗粒(VLP)和佐剂,以增强疫苗的免疫原性。本文就VLP中存在的保守抗原靶点和分子佐剂作一综述。除了分子佐剂外,还讨论了包括血凝素茎段、流感M2外区和神经氨酸酶在内的保守抗原靶点,这些分子佐剂被设计成以膜锚定的形式整合到VLP中。
Current influenza vaccines are primarily targeted to induce immunity to the influenza virus strain-specific hemagglutinin antigen and are not effective in controlling outbreaks of new pandemic viruses. An approach for developing universal vaccines is to present highly conserved antigenic epitopes in an immunogenic conformation such as virus-like particles (VLPs) together with an adjuvant to enhance the vaccine immunogenicity. In this review, the authors focus on conserved antigenic targets and molecular adjuvants that were presented in VLPs. Conserved antigenic targets that include the hemagglutinin stalk domain, the external domain of influenza M2 and neuraminidase are discussed in addition to molecular adjuvants that are engineered to be incorporated into VLPs in a membrane-anchored form.
DOI: 10.1371/journal.pone.0001501
发表时间: 2008-01-30
期刊: PloS one
影响因子: 3.7
作者:
Bright RA;Carter DM;Crevar CJ;Toapanta FR;Steckbeck JD;Cole KS;Kumar NM;Pushko P;Smith G;Tumpey TM;Ross TM
通讯作者: Ross TM
DOI: 10.1002/eji.200636959
发表时间: 2008-01-01
影响因子: 5.4
作者:
Bessa, Juliana;Schmitz, Nicole;Bachmann, Martin F.
通讯作者: Bachmann, Martin F.
DOI: 10.1128/jvi.79.12.7380-7388.2005
发表时间: 2005-06-01
影响因子: 5.4
作者:
Bianchi, E;Liang, XP;Pessi, A
通讯作者: Pessi, A
DOI: 10.1099/0022-1317-74-1-143
发表时间: 1993-01-01
影响因子: 3.8
作者:
BLACK, RA;ROTA, PA;KENDAL, AP
通讯作者: KENDAL, AP
DOI: 10.1016/j.vaccine.2006.05.082
发表时间: 2006-11-10
期刊: VACCINE
影响因子: 5.5
作者:
De Filette, Marina;Fiers, Walter;Saelens, Xavier
通讯作者: Saelens, Xavier